ZA200707486B - Use of 2-(2-nitro-4-trifluoromenthylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease - Google Patents
Use of 2-(2-nitro-4-trifluoromenthylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's diseaseInfo
- Publication number
- ZA200707486B ZA200707486B ZA200707486A ZA200707486A ZA200707486B ZA 200707486 B ZA200707486 B ZA 200707486B ZA 200707486 A ZA200707486 A ZA 200707486A ZA 200707486 A ZA200707486 A ZA 200707486A ZA 200707486 B ZA200707486 B ZA 200707486B
- Authority
- ZA
- South Africa
- Prior art keywords
- disease
- parkinson
- treatment
- cyclohexanedione
- nitro
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 3
- 229940125782 compound 2 Drugs 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- OUBCNLGXQFSTLU-UHFFFAOYSA-N nitisinone Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1C(=O)C1C(=O)CCCC1=O OUBCNLGXQFSTLU-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0504103.3A GB0504103D0 (en) | 2005-02-28 | 2005-02-28 | Novel method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200707486B true ZA200707486B (en) | 2009-02-25 |
Family
ID=34430351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200707486A ZA200707486B (en) | 2005-02-28 | 2006-02-27 | Use of 2-(2-nitro-4-trifluoromenthylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20090326072A1 (https=) |
| EP (1) | EP1853241B1 (https=) |
| JP (1) | JP2008531665A (https=) |
| CN (1) | CN101163466B (https=) |
| AT (1) | ATE524171T1 (https=) |
| AU (1) | AU2006217650B2 (https=) |
| BR (1) | BRPI0609177A2 (https=) |
| CA (1) | CA2598517A1 (https=) |
| DK (1) | DK1853241T3 (https=) |
| ES (1) | ES2374761T3 (https=) |
| GB (1) | GB0504103D0 (https=) |
| IL (1) | IL185410A0 (https=) |
| MX (1) | MX2007010480A (https=) |
| PT (1) | PT1853241E (https=) |
| RU (1) | RU2420272C2 (https=) |
| WO (1) | WO2006090177A1 (https=) |
| ZA (1) | ZA200707486B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008293542B9 (en) | 2007-08-27 | 2014-08-07 | Dart Neuroscience (Cayman) Ltd. | Therapeutic isoxazole compounds |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| MX2011004769A (es) * | 2008-11-06 | 2011-11-29 | Biotie Therapies Inc | Tratamiento de sindrome de pierna sin reposo y alteraciones del sueño. |
| EP2723320B1 (en) * | 2011-06-23 | 2016-01-13 | Swedish Orphan Biovitrum International AB | Liquid pharmaceutical composition comprising nitisinone |
| CN103622942A (zh) * | 2013-11-04 | 2014-03-12 | 江苏大学 | 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法 |
| EA201890346A1 (ru) * | 2015-07-29 | 2018-08-31 | Такеда Гмбх | Ингибитор pdf4 для лечения диабетической нефропатии |
| ITUB20160650A1 (it) | 2016-02-11 | 2017-08-11 | Dipharma S A | Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione |
| US9783485B1 (en) | 2016-11-30 | 2017-10-10 | Dipharma S.A. | Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof |
| TW202543611A (zh) * | 2024-03-27 | 2025-11-16 | 美商費斯製藥有限公司 | Ｈｐｄ抑制劑組成物及使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4780127A (en) * | 1982-03-25 | 1988-10-25 | Stauffer Chemical Company | Certain 2-(substituted benzoyl)-1,3-cyclohexanediones and their use as herbicides |
| US5092919A (en) * | 1991-01-15 | 1992-03-03 | Imperial Chemical Industries Plc | Certain 2-(2'-methyl-3',4'-trisubstituted benzoyl)-1,3-cyclohexanediones |
| EP0591275B1 (en) * | 1991-06-24 | 1999-03-31 | Zeneca Limited | Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of tyrosinaemia and pharmaceutical compositions |
| FR2777781B1 (fr) * | 1998-04-24 | 2004-04-09 | Rhone Poulenc Rorer Sa | Associations riluzole et l-dopa pour le traitement de la maladie de parkinson |
| US20050288187A1 (en) * | 2002-07-03 | 2005-12-29 | Hanauske-Abel Hartmut M | Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases |
| WO2005007096A2 (en) * | 2003-07-11 | 2005-01-27 | Merck & Co., Inc. | Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
| BRPI0621959A2 (pt) * | 2006-08-18 | 2011-12-27 | Syngenta Ltd | usos de pelo menos um composto capaz de inibir 4-hidroxifenilpiruvato dioxigenase, e de um composto ou uma composiÇço, kit, e, composiÇço farmacÊutica |
| MX2011004769A (es) * | 2008-11-06 | 2011-11-29 | Biotie Therapies Inc | Tratamiento de sindrome de pierna sin reposo y alteraciones del sueño. |
-
2005
- 2005-02-28 GB GBGB0504103.3A patent/GB0504103D0/en not_active Ceased
-
2006
- 2006-02-27 EP EP06709910A patent/EP1853241B1/en not_active Expired - Lifetime
- 2006-02-27 BR BRPI0609177-6A patent/BRPI0609177A2/pt not_active IP Right Cessation
- 2006-02-27 WO PCT/GB2006/000684 patent/WO2006090177A1/en not_active Ceased
- 2006-02-27 MX MX2007010480A patent/MX2007010480A/es not_active Application Discontinuation
- 2006-02-27 AT AT06709910T patent/ATE524171T1/de active
- 2006-02-27 ES ES06709910T patent/ES2374761T3/es not_active Expired - Lifetime
- 2006-02-27 CA CA002598517A patent/CA2598517A1/en not_active Abandoned
- 2006-02-27 AU AU2006217650A patent/AU2006217650B2/en not_active Ceased
- 2006-02-27 RU RU2007131934/15A patent/RU2420272C2/ru not_active IP Right Cessation
- 2006-02-27 JP JP2007557572A patent/JP2008531665A/ja active Pending
- 2006-02-27 DK DK06709910.1T patent/DK1853241T3/da active
- 2006-02-27 US US12/090,645 patent/US20090326072A1/en not_active Abandoned
- 2006-02-27 PT PT06709910T patent/PT1853241E/pt unknown
- 2006-02-27 ZA ZA200707486A patent/ZA200707486B/xx unknown
- 2006-02-27 CN CN2006800133878A patent/CN101163466B/zh not_active Expired - Fee Related
-
2007
- 2007-08-21 IL IL185410A patent/IL185410A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1110211A1 (en) | 2008-07-11 |
| DK1853241T3 (da) | 2012-01-16 |
| CA2598517A1 (en) | 2006-08-31 |
| GB0504103D0 (en) | 2005-04-06 |
| WO2006090177A1 (en) | 2006-08-31 |
| RU2420272C2 (ru) | 2011-06-10 |
| IL185410A0 (en) | 2008-08-07 |
| AU2006217650B2 (en) | 2011-06-09 |
| ES2374761T3 (es) | 2012-02-21 |
| CN101163466A (zh) | 2008-04-16 |
| EP1853241B1 (en) | 2011-09-14 |
| MX2007010480A (es) | 2008-02-07 |
| JP2008531665A (ja) | 2008-08-14 |
| PT1853241E (pt) | 2012-01-11 |
| ATE524171T1 (de) | 2011-09-15 |
| US20090326072A1 (en) | 2009-12-31 |
| RU2007131934A (ru) | 2009-02-27 |
| BRPI0609177A2 (pt) | 2010-02-23 |
| CN101163466B (zh) | 2011-12-07 |
| EP1853241A1 (en) | 2007-11-14 |
| AU2006217650A1 (en) | 2006-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL185410A0 (en) | Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease | |
| MX2009006742A (es) | Inhibidores acilaminopirazoles como fgfr. | |
| PT1696905E (pt) | 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson | |
| TW200635582A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| TW200728307A (en) | Novel spirochromanone derivatives | |
| EP1940373B8 (en) | 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease | |
| MY145439A (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
| WO2009025785A3 (en) | Cb2 receptor ligands for the treatment of pain | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| MX2010006204A (es) | Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| WO2009067493A3 (en) | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders | |
| DK1670903T3 (da) | Behandling af neurodegenerative sygdomme | |
| PT1778837E (pt) | Tratamento de doenças neurodegenerativas por utilização de inibidores de scd4 | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| GB0516168D0 (en) | Pharmaceutical compounds | |
| UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
| DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| TW200716152A (en) | Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture | |
| TW200635595A (en) | Medicaments for the treatment of prevention of fibrotic diseases | |
| WO2008057599A3 (en) | Methods for the treatment of abeta related disorders and compositions therefor | |
| ZA200700945B (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
| DE602007008947D1 (en) | 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3-modulatoren | |
| ZA200800999B (en) | Use of N-dibenz (b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy | |
| WO2008014232A3 (en) | Pharmaceutical formulations for the treatment of alzheimer's disease | |
| HK1164058A (en) | Specific diarylhydantoin and diarylthiohydantoin compounds |